CSPC Group (01093): Highly active insulin receptor agonist (SYH2092 injection) approved for clinical trials in China

According to the Zhitong Finance App, Shiyao Group (01093) announced that the SYH2092 injection developed by the Group has been approved by the China National Drug Administration and can conduct clinical trials in China.

This product is an amylin (Amylin) receptor agonist. By optimizing excitatory activity, the product is expected to improve efficacy while having controlled tolerability. Furthermore, by optimizing fatty acid modification, the product can extend the half-life in the body and has the potential to provide long-lasting weight loss benefits.

Preclinical studies have shown higher target stimulant activity, significant weight loss effects, and long-lasting weight loss maintenance effects compared with many insulin analogs currently in clinical development. Furthermore, when used in combination with a glucagon-like peptide-1 (GLP-1) /glucose-dependent insulin-promoting polypeptide (GIP) receptor dual bias agonist developed independently by the group, it showed a synergistic weight loss effect, increasing the amount of weight loss while extending the duration of the curative effect.

The product is expected to bring significant clinical benefits to weight management in obese patients and improve blood sugar control in adult patients with type 2 diabetes (T2DM).